Lectin drug conjugate therapy for colorectal cancer
نویسندگان
چکیده
منابع مشابه
A traceless vascular-targeting antibody-drug conjugate for cancer therapy.
Monoclonal antibodies have demonstrated considerable utility in the clinical treatment of cancer, but unmodified immunoglobulins are rarely curative, especially when used as single agents. Thus, there is considerable interest in arming antibodies with bioactive payloads (e.g., drugs, radionuclides, cytokines), to improve their potency and selectivity, thus increasing activity at the tumor site ...
متن کاملTherapy for metastatic colorectal cancer.
Median overall survival of metastatic colorectal cancer patients treated with first- and second-line combination chemotherapy now extends to more than 20 months in some studies. Chemotherapy alone, particularly when oxaliplatin is included, may allow potentially curative resection of advanced disease. There is evidence that the addition of antibodies targeted against vascular endothelial growth...
متن کاملSystemic therapy for colorectal cancer.
N Engl J Med 2005;352:476-87. Copyright © 2005 Massachusetts Medical Society. olorectal cancer is the third most common malignant disease and the second most frequent cause of cancer-related death in the United States, with 145,290 new cases and 56,290 deaths anticipated in 2005. 1 Worldwide, colorectal cancer is the fourth most commonly diagnosed malignant disease, with an estimated 1,023,000 ...
متن کاملMaintenance therapy for colorectal cancer.
Maintenance therapy has become quite a hot topic for those of us working in the field of solid tumor malignancies. Our original concept of chemotherapy for solid tumors was to give a certain number of cycles and then stop treatment, or to continue treatment until an intolerable toxicity arose. Given that we now have more management tools at our disposal, and as treatments given chronically have...
متن کاملPeptide dendrimer-Doxorubicin conjugate-based nanoparticles as an enzyme-responsive drug delivery system for cancer therapy.
Peptide dendrimers have shown promise as an attractive platform for drug delivery. In this study, mPEGylated peptide dendrimer-doxorubicin (dendrimer-DOX) conjugate-based nanoparticle is prepared and characterized as an enzyme-responsive drug delivery vehicle. The drug DOX is conjugated to the periphery of dendrimer via an enzyme-responsive tetra-peptide linker Gly-Phe-Leu-Gly (GFLG). The dendr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Science
سال: 2020
ISSN: 1347-9032,1349-7006
DOI: 10.1111/cas.14687